Shared on05 Sep 25
With little change in both net profit margin and future P/E, there has been no effective revision to Mankind Pharma's consensus analyst price target, which remains at ₹2800. What's in the News Incorporated wholly owned subsidiary in Russia under the name Mankind Pharma LLC.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.29%
AnalystConsensusTarget has decreased revenue growth from 18.3% to 16.1%.
Shared on02 Apr 25Fair value Increased 2.04%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 5.78%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.